How can we help?

Home

Autoimmune Liver Diseases IgG Profile, LIA

Also referred as

Autoimmune Liver Disease Profile

For men & women

Earliest reports in

48 hours

Contains

6 tests

Know more about this test

The Autoimmune Liver Diseases IgG Profile, LIA is a group of blood tests that helps detect several key markers associated with autoimmune liver conditions such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). These conditions occur when the immune system mistakenly attacks healthy liver cells (producing autoantibodies), leading to inflammation and potential liver damage.

Samples required

Blood

Find out

Why is this test booked?

Preparations

No special preparation is required.

Sample Collection

Who will collect your samples?

Understanding Autoimmune Liver Diseases IgG Profile, LIA

The Autoimmune Liver Diseases IgG Profile, LIA checks for specific IgG autoantibodies (proteins) linked to autoimmune liver diseases. This profile helps find out if someone has conditions like autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC). It can also help distinguish between liver conditions so that the right treatment can be initiated. It can also help distinguish between different liver conditions and rule out other problems with similar symptoms such as viral hepatitis, fatty liver disease, or drug-induced liver injury.

The profile helps detect the presence of IgG antibodies against antigens such as AMA M2, Sp100, LKM1, gp210, LC1 and SLA, using the line immunoassay (LIA) technique. Early detection and treatment are important to manage these conditions and prevent serious liver damage such as cirrhosis and liver failure.

Doctors may recommend this profile if there are symptoms such as ongoing fatigue, yellowing of the skin or eyes (jaundice), itching, abdominal discomfort, or abnormal liver function test results. The profile is also done to assess the effectiveness of the treatment or the progression of the disease over time.

No special preparation is required for the Autoimmune Liver Diseases IgG Profile, LIA. It is important to inform the doctor about all the medicines and supplements being taken, as these may affect the test results potentially requiring dosage adjustments or temporary discontinuation before the test.

Test result ranges may vary across laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results. The insights from this test help the doctor tailor an appropriate treatment plan.

What does Autoimmune Liver Diseases IgG Profile, LIA measure?

Contains 6 tests

The Autoimmune Liver Diseases IgG Profile, LIA measures the presence of specific autoantibodies that attack components of the liver and associated cells, helping confirm a diagnosis of autoimmune liver disease. These antibodies include:

AMA M2: Indicates the presence of antimitochondrial antibodies, which are specific for primary biliary cholangitis (PBC).
Sp100: Indicates antibodies against the Sp100 protein, which are associated with PBC.
gp210: Indicates antibodies against the gp210 protein, which are associated with PBC.
LKM1: Indicates the presence of anti-liver kidney microsomal antibodies type 1, which are associated with autoimmune hepatitis type 2 (AIH-2).
LC1: Indicates the presence of antibodies against the LC1 protein, which are associated with AIH-2.
SLA: Indicates the presence of antibodies against the SLA protein, which are associated with AIH.

Together, these markers provide valuable insights for diagnosing and classifying autoimmune liver diseases, particularly when clinical signs overlap or mimic other liver conditions.

AMA-M2 LIA

SP100

LKM1

GP210

LC1

SLA

Frequently booked together

FAQs related to Autoimmune Liver Diseases IgG Profile, LIA

What is the Autoimmune Liver Diseases IgG Profile, LIA?

It is a group of blood tests that checks for special IgG antibodies that may be attacking your liver by mistake. These antibodies help find out if you have an autoimmune liver problem.

Why do I need this test?

You may need this test if you have symptoms like tiredness, stomach pain, yellow eyes or skin (jaundice), or itchy skin. It helps doctors find the exact cause of your liver problem.

What antibodies does this test check for?

This test checks for several IgG antibodies, including AMA-M2 LIA, SP100, LKM1, GP210, LC1, and SLA.

Do I need to fast before this test?

No, you don’t need to fast. You can eat and drink normally unless your doctor tells you otherwise.

How is the Autoimmune Liver Diseases IgG Profile, LIA performed?

A phlebotomist will clean your skin using an antiseptic alcohol cotton swab or wipe and take blood samples from your vein using a needle. The blood sample will be stored safely and transported to the laboratory for analysis.

Is there any risk associated with the Autoimmune Liver Diseases IgG Profile, LIA?

No, the Autoimmune Liver Diseases IgG Profile, LIA is generally safe with minimal risks. You may feel slight discomfort during blood sample collection but chances of serious complications are rare.

How frequently should I get the Autoimmune Liver Diseases IgG Profile, LIA done?

The frequency of getting this test depends on individual circumstances, including whether an individual has been diagnosed with autoimmune liver disease or has risk factors for the disease. Your doctor may suggest the frequency of this testing based on your condition and your treatment response.

Can autoimmune liver diseases be cured?

There is no cure for autoimmune liver diseases. But early diagnosis and timely treatment can relieve symptoms and prevent or reverse liver damage.

How does Tata 1mg ensure accurate lab test results?

Tata 1mg ensures accurate lab test results through certified laboratories. Tata 1mg uses advanced technology and adheres to stringent quality control measures. This commitment to high standards guarantees reliable results.

Content created by

Want to know moreRead our editorial policy

Last Updated

12th Nov 2025